

# Joint Research Centre

the European Commission's in-house science service

*Serving society  
Stimulating innovation  
Supporting legislation*

**From Bedside to Bench**  
adding human context  
to *in vitro* models

**EUSAAT Annual Congress**

26<sup>th</sup> August 2016

**Brigitte Landesmann**

[www.ec.europa.eu/jrc](http://www.ec.europa.eu/jrc)

**DISCLAIMER:**

This presentation and its contents do not constitute an official position of the European Commission or any of its services. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of this presentation or its contents.




European  
Commission

# Human Health Risk Assessment

An estimation of the nature and probability of adverse health effects in humans who may be exposed to chemicals

**Focus is on People**




# The classical approach to chemical toxicity testing...

...is rather focused on animals



Animals are exposed to chemicals



and the outcome is observed



# PARADIGM SHIFT in regulatory toxicity testing and risk assessment




- to develop a more robust scientific basis for assessing adverse health effects of chemicals
- to replace, reduce, and refine the use of experimental animals (3Rs)
- to provide broad coverage of chemicals and chemical mixtures
- to reduce the cost and time of testing

# Landmark Report

## NAS 2007

### Toxicity testing in the 21<sup>st</sup> century. A vision and a strategy









“Transform toxicity testing from a system based on whole-animal testing to one founded primarily on *in vitro* methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin”



# 21<sup>st</sup> Century Toxicity Testing is here....

## We have a variety of cell models

- Primary human cells
- Immortalized human cell lines
- Induced pluripotent stem cells
- human embryonic stem cells
- Co-cultures of various cell types
- 3D cultures
- Perfusion bio-reactors
- Precision-cut organ slices
- Isolated perfused organs



## and a variety of tools


- High throughput screening
- High content imaging
- Omics techniques
- Computer modelling

**Technology is rapidly further progressing...**

# 21st Century Toxicity Testing is here....

## Nevertheless, there are important shortcomings


- Role of the immune system
- Specific organ architecture
- Limited life span of cells in culture, dedifferentiation
- Non-physiological conditions ( $O_2$ , medium,....)
- Efficacious doses, exposure



- *In vitro* models cannot mimic whole human organs
- But - the *in vivo* situation should be the benchmark
- A better understanding of **health, disease,** and **repair** mechanisms can support the identification of markers with translational relevance

# Scientific challenge:

How to make effective use of available mechanistic data and the wealth of existing scientific knowledge to support regulatory decision-making?




**Adverse Outcome Pathways  
are part of the solution.**

A tool for knowledge-based human health  
risk assessment




# Adverse Outcome Pathway

An AOP is a conceptual construct that describes a sequential chain of causally linked events starting on molecular level and leading through different levels of biological organisation to an adverse health or eco-toxicological outcome.



# Adverse Outcome Pathway (AOP)




**Molecular initiating event (MIE)** – the initial point of chemical interaction on the molecular level within an organism


**Adverse Outcome (AO)** – correspondent to an established protection goal or equivalent to an apical endpoint in an accepted regulatory guideline toxicity test

**Key Event (KE)** - A change in biological state that is both measurable and essential to the progression to a specific AO

**Key event relationship (KER)** - A scientifically-based relationship that connects one KE to another; it defines a directed relationship between the two KEs, identifying one as upstream and the other as downstream



# AOP to Liver Fibrosis



The MIE is protein alkylation, leading to structural and functional cell injury and cell death. Injured and apoptotic hepatocytes activate Kupffer cells, which are the main source of TGF- $\beta$ 1, the most potent pro-fibrogenic cytokine. TGF- $\beta$ 1 expression causes stellate cell activation, which leads to progressive collagen accumulation, changes in extracellular matrix composition and subsequently to liver fibrosis.


<https://aopwiki.org/wiki/index.php/Aop:38>


*An AOP does not provide a comprehensive molecular description of every aspect of the biology involved (the mechanism of action), but focuses on the critical steps in the pathway.*

The AOP concept systematically describes the links between causes and outcomes – potentially also describing **Pathways of Disease**.

Any chronic liver disease may result in fibrosis.

Though the causes/initiators are different, the further downstream pathway to the AO/disease remains.





There is a disconnect between the concepts and data associated with molecular/cellular studies and those associated with clinical studies.

Sharing information between these research communities, thus closing data gaps between *in vitro* findings and clinical knowledge, would be beneficial for all stakeholders.


E.g. there is a disconnect between *in vitro* DILI endpoints and the data used to assess hepatotoxicity in a clinical setting

### ***In vivo***


- Serum enzymes:
  - AST, ALT
  - ALP,  $\gamma$ GT
- Biosynthetic functions
  - Albumin
  - Immunglobulins
  - Coagulation factors
- Excretion and Detoxification
  - Bilirubin
  - Ammonia
- Others
  - Serology
  - Autoimmune markers
  - Imaging
  - Biopsy

### ***In vitro***

- Protein adducts
- Apoptosis, Necrosis
  - LDH leakage, Caspases
- Mitochondrial dysfunction
  - MMP
- Oxidative stress
  - ROS, GSH
- Kupffer cell activation
  - Cytokines
- Stellate Cell activation
  - Morphology,  $\alpha$ -SMA, collagen
- Steatosis
- Cholestasis
- Gene expression levels



# How to interrelate these findings?



## *In vivo* human data as benchmark!



**Clinical studies** to obtain *in vivo* human information, to anchor *in vitro* research models to "real-world" illnesses in humans.




**Clinical samples** from healthy persons and from patients (*ex vivo* or post-mortem) like blood, serum, urine, omics data, histology,....

Data that are regularly taken in the course of the diagnostic and curative process could support – consent provided - better understanding and improved relevance of *in vitro* testing.

Aiming at a combination of *in vitro* testing methods with human-based models and clinical data.





## The AOP framework – a tool to support


- the integration of available knowledge
- mechanistic understanding
- the identification of biomarkers
- the identification of gaps and uncertainties
- the direction of further research for closing these gaps
- the collaboration between scientists from various disciplines



# Adverse Outcome Pathway Knowledge Base (AOP-KB)

|| AOP-KB || Background || How to contribute ||

<https://aopkb.org/>



Please click on any of the AOP-KB elements you want to use.

Please note that the AOP-KB is work in progress and more elements will become available over time.

# Adverse Outcome Pathway Knowledge Base AOP KB

The AOP-KB is a combination of four individually developed platforms - AOP-Wiki, Effectopedia, AOP Xplorer and Intermediate Effects DB – with different emphasis on the type of the captured Information. All four modules (and potentially compatible third party systems) share, exchange and synchronise information via the AOP-KB Hub.

The AOP-KB project is an OECD initiative, executed in collaboration between the European Commission's Joint Research Centre (JRC), the United States Environmental Protection Agency (US EPA), and the US Army Engineer Research & Development Center (ERDC).

<https://aopkb.org/>





# AOP Wiki

The AOP-Wiki is one component of the AOP Knowledge Base that enables the scientific community to share, develop, and discuss AOP-related knowledge.

A screenshot of the AOP Wiki main page. The page has a light blue header with navigation links like 'Page', 'Discussion', 'Read', 'View source', 'View history', and a search box. The main content area is titled 'Main Page' and contains a 'Contents' table of contents with 6 items. Below the table of contents is an 'Announcements' section with a red heading and a paragraph about a major upgrade starting on November 27, 2016. The 'Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)' section follows, providing instructions for contributors. At the bottom, there are logos for ERDC, SAAOP, AOP Wiki, OECD, and the European Commission.

139.191.247.3 Talk for this IP address Create account Log in

Page Discussion Read View source View history Search

## Main Page

Aop:40 > Main Page

### Contents [hide]

- 1 Announcements
- 2 Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)
  - 2.1 Disclaimer
- 3 How to add a new AOP
  - 3.1 Before You Start
  - 3.2 OECD User Handbook
  - 3.3 Commenting on AOPs
  - 3.4 To create a new AOP
  - 3.5 To edit AOP wiki pages
  - 3.6 To edit other wiki pages (key events, MIE's, etc.)

### Announcements

To request author access to the wiki, please follow the instructions here: <http://www.saaop.org/AccessPage.html>

**Wiki Down Time!** The AOP-Wiki will be undergoing a major upgrade beginning November 27, 2016. Starting on this date, the wiki will be closed for editing until the upgrade is complete. Users will have constant access to all information in read-only mode. No new user accounts can be created during the down time. The upgrade is anticipated to last approximately one week, but it may be completed sooner. At the latest, read/write access to the new version of the AOP-Wiki will be restored by December 4, 2016.

### Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)

If you are interested in contributing AOP-related knowledge to the AOP-KB, please follow the instructions laid out at the [OECD Adverse Outcome Pathways, Molecular Screening and Toxicogenomics](#) page. The [Guidance on Developing and Assessing AOPs](#) document is the basis for all work related to contributing and sharing AOP-related knowledge. A [Users' Handbook Supplement](#) to this Guidance has been written to aid systematic development and transparent assessment of Adverse Outcome Pathways (AOPs). The handbook contains a template to guide AOP description and provides focused and practical instructions for developers and assessors intended to assist in identifying, organizing, and evaluating critical information on key events and linkages (i.e., key event relationships (KER)) within the AOP, as well as guidance on how to assess the weight of evidence supporting the overall AOP.

# Exchange between toxicology and clinical medicine



## A bedside-to-bench-to-bedside program

⇒ to inform relevant *in vitro* testing

⇒ to allow extrapolation of *in vitro* information to disease and regeneration mechanisms *in vivo*.

### collaboration

health care professionals, academia, and industry





THANKS!

## Stay in touch



**JRC Science Hub:** [www.ec.europa.eu/jrc](http://www.ec.europa.eu/jrc)



**Twitter:** @EU\_ScienceHub



**LinkedIn:** european-commission-joint-research-centre



**YouTube:** JRC Audiovisuals



**Vimeo:** Science@EC